قدِّم طلبك الآن 
الدكتور عبد الإله الرضواني
عالم أول أستاذ مشارك
الدكتور عبد الإله الرضواني
عالم أول أستاذ مشارك
الكيان
معهد قطر لبحوث الطب الحيوي
كلية العلوم الصحية والحيوية
Divison
مركز بحث السكري
السيرة الذاتية
Dr. Abdelilah Arredouani joined QBRI in March 2012 as a Scientist in the Diabetes Research Center. He holds a PhD in Biomedical Sciences from the Faculty of Medicine at University of Louvain-La-Neuve in Belgium. Prior to joining QBRI he worked in Netherlands at the Department of Neurosciences in Erasmus Medical Center in Rotterdam, in United Kingdom at the Department of Pharmacology in Oxford University, and in Qatar at the Department of Physiology and Biophysics in Weill Cornell Medicine. During his PhD, he studied the contribution of the calcium stores in the endoplasmic reticulum to glucose-induced calcium response and insulin secretion from the pancreatic beta cell in the context of type 2 diabetes.
Dr. Arredouani was a key player in the discovery of the NAADP receptor, the two pore channels, and Ned-19, a specific antagonist of the NAADP. Since joining QBRI in 2012, Dr. Arredouani has been involved in projects related to the identification of biomarkers to predict type 2 diabetes using systems biology approaches. He has published in high impact peer-reviewed journals including Nature, Nature Chemical Biology, Current Biology, Diabetes and JBC.
- Fatty liver, Lifestyle and Glycaemia (FLAG): The impact of a low energy diet Intervention on non-alcoholic fatty liver disease in Type 2 Diabetes in Qatar.
- Investigation of the association between low salivary alpha-amylase and risk of metabolic disorders in the Qatari population.
- Mechanisms underlying the improvement of NAFLD by GLP-1 agonists.
Course Coordinator ( Teaching )
Advances in human metabolism and disease (LS642)
Tutor ( Teaching )
Signal Transduction in Health and Diseases (LS641)
Tutor ( Teaching )
OMICS (GPM 603)
Committees
Life Science Graduate Advisory committee
MENTORING
Khaoula Eraafii: P.h.D student
- Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline. Int J Mol Sci. 2022; 23(11):6144.
- Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism. Biomedicines. 2022;10(5):1020.
- Identification of Novel Circulating miRNAs in Patients with Acute Ischemic Stroke. Int J Mol Sci. 2022 Mar 21;23(6):3387.
- Elevated levels of salivary α- amylase activity in saliva associated with reduced odds of obesity in adult Qatari citizens: A cross-sectional study. Plos One. 2022 Mar 10; 17(3):e0264692. Al-Akl N, Thompson IR, Arredouani A*.
- Reduced odds of diabetes associated with high plasma salivary α-amylase activity in Qatari women: a cross-sectional study. Sci Rep. 2021 Jun 1;11(1):11495.
- Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. Sci Rep. 2022 Feb 9;12(1):2226.
- Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4. J Transl Med. 2021 Jun 2;19(1):235.
Metabolomic Profile of Low Copy-Number Carriers at the Salivary Alpha-Amylase Gene Suggests a Metabolic Shift Towards Lipid-Based Energy Production. Diabetes. 2016 Nov;65(11):3362-3368
Beverley Balkau, Amélie Bonnefond; Philippe Froguel. Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling. Mol Metab. 2016 Aug 23;5(10):918-25
Role for NAADP activation of two-pore channels in stimulus-secretion coupling in mouse pancreatic beta cells, J Biol Chem. 2015 Aug 28;290(35):21376-92
Mechanisms behind the immediate effects of Roux-en-Y gastric bypass surgery on type 2 diabetes, Theor Biol Med Model. 2013 Jul 13;10(1):45.
NAADP mobilizes calcium from acidic organelles through two-pore channels. Nature. 2009 May 28;459(7246):596-600.
Identification of a chemical probe for NAADP by virtual screening. Nat Chem Biol. 2009 Feb 22.
List of Publications on Pubmed
- $329,095 (Lead Principal Investigator) IGP-2-QBRI. Fatty liver, Lifestyle and Glycaemia (FLAG): The impact of a low energy diet Intervention on non-alcoholic fatty liver disease in type 2 diabetes (2017-2020).
- $251,041 (Co-PI) from IGP2-QBRI. Effect of incretin-based therapy combined with lifestyle intervention on improving -cell function and attenuating metabolic stress in pre-diabetic Qatari subjects: A pilot study (2017-2020).
- $696,522 (Co-Principal Investigator) from NPRP10-QNRF. Metabolic and molecular profiling of lean and obese subjects with T2DM in Qatar in response to a lifestyle intervention protocol: Possible effect of body fat distribution (2017-2021).